FP7Reintegration grant2013–2017

FREE-FLOW · Dynamic Microfluidic Deflection Systems for High Throughput Single Platelet Function Testing

FP7 — People (Marie Curie Actions)

Duration
2013-08-01 → 2017-07-31
EU contribution
€100,000
Participants
1
Scheme
MC-CIG

Lines connect the coordinator with its partners.

Results in brief

Dynamic Microfluidic Deflection Systems for High Throughput Single Platelet Function Testing

The research has entailed the design and development of a high throughput technology to measure single platelet functional capacity. The technology is required to understand platelet population functional distribution and how this determines homeostasis in health with extrapolation to understand imbalance in disease leading to heart attacks and strokes. A droplet microfluidic platform was integrated to a multiplexed flow cytometry instrument for high throughput single platelet stimulation and the determination of activation via alphaIIbbeta3 activation (inside out signalling), P-selectin presentation (degranulation) and annexin V exposure (membrane inversion). Critically, droplet encapsulation prevents paracrine cross-talk to definitively ascertain single platelet sensitivities and by comparison with platelet collective experiments understand the global impact. For 3 different agonists, convulxin, ADP and TRAP14, platelets from a donor have highly variable sensitivities that are not heterogeneous, rather a continuum of sensitivities. This is not due to platelet volume or GP6 receptor count, with efforts on-going to determine if platelet age is a determining factor. Alternatively, the origin, the production of thousands of platelets from a single megakaryocyte, is a highly asymmetric process and make account for the continuous variability. The consequence of varied sensitivity is that platelet collectives operating together have approx. 10-fold gains in sensitivity than the majority of the platelet population when measured singularly. Thus hypersensitive platelets exist and have been measured, representing hypersensitive sentinels that orchestrate global behaviour. This is at the root of understanding homeostasis and how imbalance can lead to disease resulting in heart attacks and strokes. Following on from this we went on to address the collagen- and thrombin-activated (COAT) platelet theory, in which functional heterogeneity is thought to be guided extrinsically, as the clot forms in space and time. In droplet microfluidic studies, we determine that intrinsic functional heterogeneity exists to a large degree, and this either augments or replaces the concept of extrinsic heterogeneity. The basic line of research has involved multiple donors and multiple repeats. Platelet population sensitivities from an individual vary on a day-to-day basis and individuals have differing sensitivities. The results thus promote research extension to (i) determine if platelet population distributions represent a useful prognostic biomarker, (ii) identify the causes of hypersensitivity for the development of novel, possibly personalised anti-platelet therapies. The research has created a paradigm shift in platelet biology, with capacity to monitor predisposition to heart attack and strokes and identify new treatment approaches, to reduce the socio-economic burden. The funding has allowed the researcher to establish himself as a lecturer in the faculty of medicine at the University of Southampton and by supervision train a platelet biologist on the development and use of microfluidics to extend biological enquiry.

Data: CORDIS, © European Union

Project objective

Single activated platelets can activate other platelets to drive blood clotting. Single, hyper-sensitive platelets could coordinate clotting in healthy individuals or cause pathological clotting in high risk groups such as the elderly, obese peoples and smokers. To identify potentially rare hypersensitive platelets, an assay must enable high throughput population profiling with all platelets isolated to avoid cross-talk. Platelet activation is associated with a <5 second transformation from a discoid to a stellate morphology and with zeta-potential changes caused by membrane inversion. However, heterogeneity within the population prevents the fractionation of hypersensitive platelets using size and charge based deflection fields. The proposed research aims to solve these challenges using bespoke microfluidic platforms integrating a biochemical switch with deterministic lateral displacement or free-flow electrophoresis deflection fields for imaging platelet trajectories DURING activation. Critically, TRAJECTORY CHANGES, consistent with platelet reorganisation dynamics, are DIAGNOSTIC for ACTIVATION and the continuous flow format generates a single-file platelet stream, effectively isolating platelets from one another. Effective size, shape and charge components of deflection will be elucidated to provide new insights into platelet activation dynamics. Platelets from healthy and high risk cohorts will be screened to identify hyper-sensitive populations and determine therapeutic doses required to desensitise the hypersensitive platelets. This multidisciplinary research will create a paradigm shift, from a population to a single platelet perspective. This discovery to diagnostics work program has great potential to generate intellectual property to underpin commercialization of a point of care diagnostic for life-long health care in the EC. Outputs from this research will also feedback to identify new challenges and opportunities in separation science.""

Original text from CORDIS.

Participants

Links

Data: CORDIS, © European Union